We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 45.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$2.31B 19.24%
9,039,652
-89,579
-1% -$17.3M
INCY icon
2
Incyte
INCY
$25.9B
$1.36B 11.32%
14,845,559
– –
GEVA
3
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$1.14B 9.46%
11,660,432
+1,000,000
+9% +$106M
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$1.02B 8.49%
28,876,712
+1,014,992
+4% +$34.6M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$667M 5.55%
20,481,442
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.9B
$523M 4.35%
4,200,456
+486,506
+13% +$51.5M
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$417M 3.47%
13,656,942
+624
+0% +$19.8K
ANAC
8
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$243M 2.02%
4,204,702
– –
NVTA
9
DELISTED
Invitae Corporation
NVTA
$110M 0.91%
+6,554,967
New +$121M
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$103M 0.86%
+1,327,451
New +$76.4M
DYAX
11
DELISTED
DYAX CORPORATION
DYAX
$101M 0.84%
6,021,485
-136,304
-2% -$2.12M
BLCM
12
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$97.1M 0.81%
419,059
-9,314
-2% -$2.25M
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.44B
$94.6M 0.79%
10,478,204
-235,482
-2% -$2.44M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$82.2M 0.68%
2,805,074
+425,000
+18% +$9.97M
CERS icon
15
Cerus
CERS
$566M
$56.5M 0.47%
13,553,275
+1,850,548
+16% +$9.48M
ARAV
16
DELISTED
Aravive, Inc. Common Stock
ARAV
$54.7M 0.45%
496,233
+115,942
+30% +$13.6M
XOMA
17
DELISTED
Xoma
XOMA
$53.5M 0.45%
735,431
-110,770
-13% -$8.13M
XNPT
18
DELISTED
XENOPORT, INC.
XNPT
$46.3M 0.39%
6,508,622
-395,006
-6% -$3.06M
ARRY
19
DELISTED
Array Biopharma Inc
ARRY
$41.7M 0.35%
5,658,755
+4,224,958
+295% +$30.1M
HRTX icon
20
Heron Therapeutics
HRTX
$60.4M
$37.9M 0.32%
2,607,784
– –
DBVT
21
DBV Technologies
DBVT
$914M
$35.5M 0.3%
151,923
– –
INSM icon
22
Insmed
INSM
$27.5B
$32.9M 0.27%
1,583,490
+475,640
+43% +$8.38M
CPRX
23
DELISTED
Catalyst Pharmaceutical
CPRX
$32.8M 0.27%
7,565,462
+850,000
+13% +$3.06M
HALO icon
24
Halozyme
HALO
$12.3B
$32.1M 0.27%
2,248,152
-527,991
-19% -$7.61M
TGTX icon
25
TG Therapeutics
TGTX
$8.31B
$31.7M 0.26%
2,050,313
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2015 Portfolio in Review

As of Q1 2015, Julian Baker held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier.

Against the trend, Julian Baker opened a new position in Invitae Corporation worth $110M.

  • Julian Baker's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Julian Baker added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Julian Baker's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Julian Baker fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Julian Baker's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Julian Baker opened 18 new positions and closed 10 in Q1 2015.
  • Julian Baker's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.